Ligand appoints Dr. Jennifer Cochran to board; moves headquarters to Emeryville, CA

LIGAND PHARMACEUTICALS INC

Dr. Jennifer Cochran appointed to board effective July 12, 2021; co-founder of xCella acquired by Ligand in Dec 2020.
Cochran receives RSUs (1,161 shares) and options (4,508 shares at $126.36) vesting over 3 years plus cash comp.
Corporate headquarters moved to 5980 Horton Street, Suite 405, Emeryville, CA 94608 effective July 14, 2021; phone unchanged.
Cochran is Shriram Chair of Bioengineering at Stanford, co-founded Red Tree Venture Capital, and serves on multiple biotech boards.

item 5.02 item 7.01 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Jennifer Cochran

Director

LGND · LIGAND PHARMACEUTICALS INC

Effective: 2021-07-12
Filed: July 14, 2021, 7:59 PM ET

Effective as of July 12, 2021, the Board of Directors of Ligand Pharmaceuticals Incorporated (the “Company”) appointed Jennifer Cochran, Ph.D., to the Company’s Board of Directors.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jennifer Cochran was appointed as Director at LIGAND PHARMACEUTICALS INC.

Action: appointed
Role: Director

Exact text from the filing

Effective as of July 12, 2021, the Board of Directors of Ligand Pharmaceuticals Incorporated (the “Company”) appointed Jennifer Cochran, Ph.D., to the Company’s Board of Directors.

View on SEC.gov

LIGAND PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0000886163-21-000102

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.